Enable Accessibility Enable Accessibility

Access to Medicines

At Takeda, we believe access to healthcare, medicines and vaccines is a priority for people globally. However, across the world, more than two billion people today cannot access the healthcare they need when facing serious, complex and rare diseases.

As a global biopharmaceutical leader, we are committed to translate science into highly-innovative medicines to make a difference to people’s lives wherever they are. Increasing access to innovative medicines for complex and rare diseases is challenging and needs collective action with deep collaboration and lasting commitments between partners.

It must be approached in a sustainable and targeted way, to strengthen and transform healthcare systems, at every stage of the patient journey - from awareness and diagnosis, to treatment, and ongoing patient support.

R&D also plays a critical role by providing patient access to our innovative, investigational medicines through R&D clinical trials and early access programs as well as by exploring ways to enhance the participation of underrepresented patient populations in these programs. Going beyond new medicines, our global R&D team is also sharing their scientific and technical knowledge with partners across multiple sectors to help strengthen health research and delivery systems to address barriers at every stage of the patient journey.

Our Access to Medicines Progress

Read more about our Access to Medicines programs in the 2020 Progress Report to see how we are improving access to quality care and treatment for patients in countries that lack strong healthcare systems.


About the Report:

With the launch of Takeda’s Access to Medicines strategy in 2016 and the inaugural Progress Report published in 2019, we have strived to mobilize collective action to drive long-term positive impact for patients by strengthening local healthcare systems in a sustainable way.

The 2020 Progress Report outlines our commitment to increase patient access to innovative medicines and elevating standards of healthcare in complex and rare diseases as well as charting the progress we have made in this space.  Via a practical framework we are also tracking the impact of our programs on health systems and on patient outcomes, with an ambition for this to become an industry best-practice tool for measurement.

Watch Susanne Weissbäcker, Takeda’s Global Head of Access to Medicines, and Katie Dain, CEO, NCD Alliance, discuss the evolution of Takeda’s Access to Medicines strategy, the lessons we’ve learned, and how we’ve used these insights to elevate our efforts and improve our programs.

Measuring Impact

We have created an Impact Framework with partners to go beyond traditional Access to Medicines metrics and emphasize local health impact, population health improvement, and health systems strengthening more directly. Developed by an academic institution this measurement tool includes inputs from industry peers, healthcare organizations, governments and NGOs. Takeda’s ambition is for this to be implemented across healthcare industries to create a single and consistent way of measuring impact to improve the lives of patients



Our Approach and Our Position

We have created a practical framework to increase sustainable access of our innovative medicines for complex and rare diseases in low- and middle-income countries (LMICs).



Hear from Patients

Takeda’s Access to Medicines approach is centered on patients’ needs. Our programs are focused on strengthening countries’ healthcare systems at every stage of the patient journey.



Driving Impact with Partners

Complex access challenges require deep collaboration and lasting commitments between partners across the public and private sectors. Learn more about how we drive impact for patients with our partners.



Pre-Approval Access

To understand how Takeda is making pre-approval medicines available to patients, click on the link below.


Access to Medicines Stories

World must work together to bring universal health coverage by 2030